Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage live biotherapeutics company that regularly issues news about its microbiome-based drug programs, regulatory interactions, and corporate developments. The company focuses on oral live biotherapeutics for medically vulnerable patient populations, particularly adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) and other high-risk groups.
News about Seres often centers on its lead investigational candidate SER-155, including Phase 1b clinical data showing a significant reduction in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia in allo-HSCT patients compared with placebo. Updates also cover regulatory designations for SER-155, such as Breakthrough Therapy and Fast Track status, and detailed feedback from the U.S. Food and Drug Administration on the design of a planned Phase 2 study.
Investors and followers of MCRB can expect announcements on clinical trial progress, investigator-sponsored studies in areas like immune checkpoint inhibitor–related enterocolitis, and research presentations at major medical meetings. Seres also issues press releases on mechanistic publications for its live biotherapeutics, including VOWST™, and on data generated from its MbTx® platform that support its broader live biotherapeutic strategy.
In addition to R&D updates, Seres publishes news on cost-reduction actions, cash runway expectations, leadership changes, and efforts to secure capital or partnerships to advance its pipeline. For those tracking MCRB, this news feed provides a centralized view of program milestones, scientific data, regulatory interactions, and corporate actions that shape the company’s live biotherapeutics portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Seres Therapeutics has secured a
The initial
With VOWST's FDA approval in April 2023, Seres aims to lead in microbiome therapeutics. The partnership with Oaktree is vital for Seres’ growth, addressing significant medical needs.
Seres Therapeutics announced that the FDA has approved VOWST (fecal microbiota spores, live-brpk), the first orally administered microbiota-based therapeutic for preventing recurrent C. difficile infection (CDI) in adults post-antibacterial treatment. The approval follows the successful Phase 3 ECOSPOR III study, which indicated that 88% of treated patients were recurrence-free at eight weeks. VOWST is expected to be available in June 2023, with a milestone payment of $125 million to Seres from Nestlé Health Science linked to the FDA approval. The joint commercialization effort aims to address a significant unmet medical need as recurrent CDI is a leading cause of hospital-acquired infections. The product does not treat CDI but aims to prevent its recurrence.
On April 5, 2023, Seres Therapeutics (Nasdaq: MCRB) announced the granting of inducement equity awards totaling 22,000 shares to three new employees. This includes options for 11,000 shares and restricted stock units (RSUs) for another 11,000 shares. The stock options have an exercise price of $5.61 per share and will vest over a specified schedule, rewarding employees for their service. This grant is part of the 2022 Employment Inducement Award Plan, which allows the company to incentivize new employees under Nasdaq rules. This announcement is part of Seres' strategy to attract and retain talent in the competitive biotech sector, enhancing its operational capacity to develop microbiome therapeutics.
Seres Therapeutics, a leading microbiome therapeutics company (Nasdaq: MCRB), announced that CEO Eric Shaff will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 8:40 a.m. ET. The presentation will be accessible via an audio webcast on Seres' website, with a replay available for 21 days after the event.
Seres is pioneering novel multifunctional bacterial consortia aimed at treating diseases. Its SER-109 program has achieved positive clinical results, gaining FDA Breakthrough Therapy and Orphan Drug designations for preventing recurrent C. difficile infections. The company is also advancing SER-155 in a Phase 1b study targeting gastrointestinal infections and other conditions.
Seres Therapeutics (MCRB) reported its 2022 financials and business updates, highlighting the FDA's review of its SER-109 Biologics License Application, with a target decision date of April 26, 2023. SER-109 is an oral microbiome therapeutic aimed at recurrent C. difficile infection (rCDI), showing an 88% success rate in preventing recurrence in trials. Commercial launch is expected soon after FDA approval. The company also advances SER-155, with preliminary data expected in May 2023. Despite a significant net loss of $250.2 million in 2022, Seres anticipates a $125 million milestone payment upon SER-109's approval.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on March 1, 2023, the grant of inducement equity awards totaling 15,500 shares to three new employees. The awards comprise 9,250 stock options and 6,250 restricted stock units (RSUs), issued under the Company's 2022 Employment Inducement Award Plan.
The options have an exercise price of $5.15 per share and will vest over time, with 25% vesting after one year and the remainder vesting quarterly. This plan aims to attract talent in compliance with Nasdaq rules.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
